Jason Gotlib

Dr. Jason Gotlib is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine / Stanford Cancer Institute. His medical school, internal medicine, and hematology/oncology fellowship training were undertaken at Stanford, where he also earned a master’s degree in clinical epidemiology.

His research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, with a focus on KIT inhibitors for systemic mastocytosis (SM). Dr. Gotlib has authored more than 250 research articles, chapters, and reviews that have been published in journals including Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine. He is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms, and chaired the NCCN guideline development for SM. He led the clinical development of midostaurin and avapritinib for patients with advanced SM, as well as response criteria for these diseases which are used by regulatory agencies for drug approval. Dr. Gotlib was awarded the European Competence Network on Mastocytosis (ECNM) Medal as Researcher of the Year in 2019 for the development of KIT-targeting therapies in advanced SM.

Dr. Gotlib currently serves as President of the American Initiative in Mast Cell Diseases (AIM). He is actively involved with the American Society of Hematology where he has served as Editor-in-Chief of ASH’s The Hematologist, was Educational Co-Chair for the 2019 annual meeting and currently serves as Associate Editor for Blood. Dr. Gotlib enjoys landscape photography in his spare time.

Gail J.Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA.

Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital.

Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Dr. Beck is an Assistant Professor in the Center for Human Genetics and Genomics, and the Department of Medicine, Division of Rheumatology at New York University Grossman School of Medicine. Prior to his joining the faculty at NYU, Dr. Beck was a postdoctoral fellow in the lab of Dr. Dan Kastner at the National Institutes of Health, where he helped in identify the role of somatic mutations in autoinflammatory diseases. He completed his B.A. from Brown University, and M.D. and Ph.D. in Biochemistry in the Medical Scientist Training Program at NYU with Dr. Danny Reinberg. He completed his Internal Medicine training at Columbia University as part of the Clinician Scientist Pathway and his Clinical Genetics fellowship at the National Institutes of Health. Dr. Beck’s research interests focus on trying to identify genetic causes of diseases in patients with rheumatic diseases, and using laboratory investigation to help provide insights for clinical care. He runs a translational program studying autoinflammatory diseases, including VEXAS syndrome, both in the clinic and in the laboratory. His work has won awards from National Institutes of Health, the Arthritis Research Foundation, Burroughs Wellcome Fund Career Award for Medical Scientist and the Henry Kunkel Society to name a few.

Dr. Jason Gotlib is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine / Stanford Cancer Institute. His medical school, internal medicine, and hematology/oncology fellowship training were undertaken at Stanford, where he also earned a master’s degree in clinical epidemiology.

His research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, with a focus on KIT inhibitors for systemic mastocytosis (SM). Dr. Gotlib has authored more than 250 research articles, chapters, and reviews that have been published in journals including Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine. He is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms, and chaired the NCCN guideline development for SM. He led the clinical development of midostaurin and avapritinib for patients with advanced SM, as well as response criteria for these diseases which are used by regulatory agencies for drug approval. Dr. Gotlib was awarded the European Competence Network on Mastocytosis (ECNM) Medal as Researcher of the Year in 2019 for the development of KIT-targeting therapies in advanced SM.

Dr. Gotlib currently serves as President of the American Initiative in Mast Cell Diseases (AIM). He is actively involved with the American Society of Hematology where he has served as Editor-in-Chief of ASH’s The Hematologist, was Educational Co-Chair for the 2019 annual meeting and currently serves as Associate Editor for Blood. Dr. Gotlib enjoys landscape photography in his spare time.

Dr. Kaner is the Director of the Inpatient Leukemia Service at Weill Cornell Medicine. He is also Director of the HLH Consult service and the HLH clinical and translational research program. He specializes in the diagnosis and management of inpatients with acute leukemias (ALL,AML, APL, MPAL, AUL), and other bone marrow disorders including aplastic anemia, MDS, CML, MPN and HLH. In addition, Dr. Kaner is the Associate Director of the Hematology and Medical Oncology Fellowship Program.

Dr. Kaner is a clinical investigator and focuses his clinical and research practice on improving outcomes for patients with various types of acute leukemia and hemophagocytic lymphohistiocytosis.